Globus Medical Inc (GMED) reports a 61% annual revenue increase and outlines strategic plans following the Nevro acquisition.

Globus Medical, Inc. GMED reported fourth-quarter 2024 adjusted earnings per share (EPS) of 84 cents, which beat the Zacks ...

In a report released today, David Turkaly from JMP Securities reiterated a Hold rating on Globus Medical (GMED – Research Report). The ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Globus Medical (GMED – Research Report), Glaukos ...

Globus Medical (NYSE:GMED) shares dipped today despite fourth-quarter results that came in ahead of the consensus forecast.

Globus Medical saw a strong 2024 with multiple new product launches and more innovation is on the way, President and CEO Dan Scavilla said in a Feb. 20 earnings ...